Becton, Dickinson and (NYSE:BDX) Releases FY 2022 Earnings Guidance

Becton, Dickinson and (NYSE:BDXGet Rating) issued an update on its FY 2022 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $11.28-$11.35 for the period, compared to the consensus estimate of $11.24. The company issued revenue guidance of $18.75 billion-$18.83 billion, compared to the consensus revenue estimate of $18.63 billion. Becton, Dickinson and also updated its FY22 guidance to $11.28-11.35 EPS.

Becton, Dickinson and Price Performance

Shares of Becton, Dickinson and stock traded up $1.72 on Friday, hitting $254.23. The company had a trading volume of 1,040,260 shares, compared to its average volume of 855,635. The business has a 50-day simple moving average of $244.97 and a 200-day simple moving average of $256.22. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.35 and a quick ratio of 1.04. The company has a market cap of $72.47 billion, a PE ratio of 43.83, a PEG ratio of 3.41 and a beta of 0.59. Becton, Dickinson and has a 52 week low of $231.46 and a 52 week high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter last year, the firm earned $2.74 EPS. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. Research analysts expect that Becton, Dickinson and will post 11.18 EPS for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be given a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 60.00%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an equal weight rating to an overweight rating and set a $275.00 price objective for the company in a report on Friday, June 24th. Piper Sandler lowered their target price on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. Stifel Nicolaus decreased their price target on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. Morgan Stanley cut their target price on Becton, Dickinson and from $282.00 to $272.00 and set an overweight rating for the company in a research note on Friday, July 15th. Finally, Citigroup downgraded Becton, Dickinson and from a neutral rating to a sell rating and decreased their target price for the company from $265.00 to $235.00 in a report on Monday, July 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. According to data from, the company has an average rating of Hold and an average target price of $270.88.

Insider Buying and Selling at Becton, Dickinson and

In related news, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total value of $115,180.00. Following the completion of the sale, the vice president now owns 1,058 shares of the company’s stock, valued at $275,080. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and

A number of institutional investors have recently added to or reduced their stakes in BDX. Equitable Holdings Inc. acquired a new position in Becton, Dickinson and in the 1st quarter valued at $341,000. KB Financial Partners LLC raised its stake in Becton, Dickinson and by 13.4% during the first quarter. KB Financial Partners LLC now owns 1,199 shares of the medical instruments supplier’s stock worth $319,000 after acquiring an additional 142 shares during the period. Orion Portfolio Solutions LLC increased its stake in shares of Becton, Dickinson and by 10.7% in the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier’s stock valued at $314,000 after purchasing an additional 114 shares during the period. SS&H Financial Advisors Inc. acquired a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $309,000. Finally, Edgestream Partners L.P. acquired a new position in Becton, Dickinson and in the first quarter worth approximately $284,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with's FREE daily email newsletter.